Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of Zoetis Inc (NYSE:ZTS) by 1.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 104,385 shares of the company’s stock after buying an additional 1,838 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Zoetis were worth $12,285,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in ZTS. State Street Corp increased its position in shares of Zoetis by 1.4% during the fourth quarter. State Street Corp now owns 19,883,222 shares of the company’s stock worth $2,631,544,000 after acquiring an additional 283,233 shares during the period. Polen Capital Management LLC grew its stake in Zoetis by 2.8% in the fourth quarter. Polen Capital Management LLC now owns 10,826,159 shares of the company’s stock worth $1,432,842,000 after purchasing an additional 293,598 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Zoetis by 5.4% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 7,964,958 shares of the company’s stock worth $1,054,162,000 after purchasing an additional 407,291 shares during the period. Geode Capital Management LLC increased its holdings in Zoetis by 21.6% during the 4th quarter. Geode Capital Management LLC now owns 7,851,668 shares of the company’s stock worth $1,037,275,000 after purchasing an additional 1,392,660 shares during the period. Finally, Nuveen Asset Management LLC raised its position in Zoetis by 2.7% during the 4th quarter. Nuveen Asset Management LLC now owns 7,765,484 shares of the company’s stock valued at $1,027,762,000 after purchasing an additional 205,267 shares in the last quarter. 91.35% of the stock is owned by institutional investors.
Shares of Zoetis stock traded down $0.22 during trading on Friday, reaching $130.11. The company’s stock had a trading volume of 1,594,563 shares, compared to its average volume of 2,399,752. The company has a quick ratio of 1.91, a current ratio of 2.77 and a debt-to-equity ratio of 2.22. The company has a market cap of $61.90 billion, a price-to-earnings ratio of 35.13, a P/E/G ratio of 4.65 and a beta of 0.78. Zoetis Inc has a 1-year low of $90.14 and a 1-year high of $146.26. The company has a 50-day simple moving average of $125.87 and a two-hundred day simple moving average of $128.04.
Zoetis (NYSE:ZTS) last announced its earnings results on Wednesday, May 6th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.86 by $0.09. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. Zoetis had a return on equity of 67.72% and a net margin of 25.41%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.88 EPS. As a group, analysts anticipate that Zoetis Inc will post 3.32 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 17th will be given a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.61%. The ex-dividend date is Thursday, July 16th. Zoetis’s payout ratio is currently 21.98%.
Several equities analysts have recently commented on ZTS shares. Credit Suisse Group restated a “buy” rating and set a $147.00 price target on shares of Zoetis in a research note on Monday, May 18th. Bank of America reissued a “hold” rating and set a $145.00 target price on shares of Zoetis in a research report on Wednesday, February 12th. SunTrust Banks reaffirmed a “hold” rating and issued a $145.00 price target on shares of Zoetis in a research report on Friday, February 14th. Morgan Stanley dropped their price objective on shares of Zoetis from $148.00 to $125.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 2nd. Finally, G.Research raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Tuesday, March 31st. Seven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Zoetis has a consensus rating of “Buy” and an average price target of $139.00.
In other Zoetis news, EVP Roxanne Lagano sold 4,463 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $131.02, for a total value of $584,742.26. Following the completion of the transaction, the executive vice president now owns 40,143 shares of the company’s stock, valued at $5,259,535.86. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Glenn David sold 43,778 shares of Zoetis stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $140.89, for a total transaction of $6,167,882.42. Following the sale, the chief financial officer now owns 36,885 shares of the company’s stock, valued at $5,196,727.65. The disclosure for this sale can be found here. Insiders sold a total of 66,844 shares of company stock valued at $9,264,589 over the last quarter. 0.17% of the stock is owned by company insiders.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: What are benefits of a growth and income fund?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.